Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.54 |
| ▸ | JAK1 | P23458 | 2/20 | 0.54 |
| ▸ | TYK2 | P29597 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169433 | 0.91 | MEN1 (0.47) | BTKHPGDRXFP1JAK2JAK3 | |
| SCHEMBL10169371 | 0.86 | STAT6 (0.55) | SYK | |
| SCHEMBL10168754 | 0.84 | BTK (0.68) | BTKHPGDRXFP1JAK2JAK3 | |
| SCHEMBL10169402 | 0.81 | SYK (0.61) | HPGDJAK2JAK3SYKLCK | |
| SCHEMBL894650 | 0.80 | BTK (0.56) | BTKHPGDRXFP1JAK2JAK3 | |
| SCHEMBL893942 | 0.80 | BTK (0.65) | BTKHPGDRXFP1JAK2JAK3 | |
| SCHEMBL10169403 | 0.79 | SYK (0.44) | JAK2JAK1TYK2SYKCSF1R | |
| SCHEMBL10169338 | 0.79 | SYK (0.52) | BTKSYKEGFR | |
| SCHEMBL894575 | 0.77 | BTK (0.55) | BTKHPGDRXFP1JAK3SYK | |
| SCHEMBL20998489 | 0.77 | BTK (0.76) | BTKHPGDRXFP1JAK3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | BTK 2/4885HPGD 225/4885RXFP1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.